Link Explored for NSAID Use, Hormonal Contraception, VTE Risk
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 11, 2023 -- In women of reproductive age, nonsteroidal anti-inflammatory drug (NSAID) use is associated with venous thromboembolism, with significantly more additional events with concomitant use of high-/medium- versus low-/no-risk hormonal contraception, according to a study published online Sept. 6 in The BMJ.
Amani Meaidi, M.D., Ph.D., from the University of Copenhagen in Denmark, and colleagues conducted a nationwide cohort study involving 2,029,065 women aged 15 to 49 years living in Denmark during 1996 and 2017 with no medical history of any venous or arterial thrombotic event, cancer, thrombophilia, hysterectomy, bilateral oophorectomy, sterilization, or infertility treatment to examine the influence of concomitant use of hormonal contraception and NSAIDs on the risk for venous thromboembolism.
The researchers identified 8,710 venous thromboembolic events among the cohort of women followed for 21.0 million person-years. Use of NSAIDs versus nonuse was associated with an adjusted incidence rate ratio for venous thromboembolism of 7.2 in women not using hormonal contraception and of 11.0, 7.9, and 4.5 in women using high-, medium-, and low-/no-risk hormonal contraception, respectively. Compared with nonuse of NSAIDs, the corresponding numbers of extra venous thromboembolic events per 100,000 women during the first week of NSAID treatment were four in women not using hormonal contraception and 23, 11, and three in women using high-, medium, and low-/no-risk hormonal contraception, respectively.
"Considering the highly prevalent indications for use of hormonal contraception and of NSAIDs, studying this association further would be of public interest, especially in regular users of NSAIDs, who might benefit from a low/no risk hormonal contraceptive rather than a high/medium risk hormonal contraceptive," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Decrease in Oral Contraceptive Fills Seen After Dobbs Ruling
WEDNESDAY, June 26, 2024 -- The Dobbs v Jackson Women's Health Organization decision, allowing states to strengthen restrictions on abortion access, was associated with declines...
ENDO: Novel Male Contraceptive Gel May Achieve Faster Sperm Suppression
WEDNESDAY, June 12, 2024 -- A novel male contraceptive gel suppresses sperm production faster than other hormone-based methods for male birth control, according to a phase 2 study...
AAN Issues Guideline for Use of Antiseizure Meds in People of Childbearing Potential
FRIDAY, May 17, 2024 -- In a practice guideline issued by the American Academy of Neurology, along with the American Epilepsy Society and the Society for Maternal-Fetal Medicine...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.